Calcimedica reports second quarter 2025 financial results and provides clinical & corporate updates

Enrollment ongoing in phase 2 kourage trial of auxora™ in acute kidney injury (aki) with respiratory failure; data expected in early 2026  productive initial meeting with the fda on auxora in acute pancreatitis (ap); conversations continue, with alignment on a pivotal trial anticipated around the end of 2025 cash position expected to fund operations into mid-2026 la jolla, calif. , aug. 12, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the second quarter ended june 30, 2025 and provided clinical and corporate updates.
CALC Ratings Summary
CALC Quant Ranking